"The opportunity to partner with Biomoda on this innovative study of lung cancer in veterans opens the door to more broadly demonstrate the benefits that our easy to use and minimally invasive technology can provide to patients everywhere. The study also provides further evidence of the vast number of potential applications for the Lung Flute(R)," said Terry Cryan, President and CEO of Medical Acoustics.
Dr. Nicolaas J. Smit, Medical Acoustics' Vice President of Science and Technology, added, "As the unique properties of the Lung Flute(R) become apparent to practitioners, we believe the opportunities for early detection of lung cancer will increase significantly. Our participation in this study offers an important opportunity to learn more about the treatment of all diseases of the pulmonary system."
Biomoda, Inc. is a developmental stage company engaged in developing biopharmaceutical technology to diagnose and treat human diseases. The Company currently licenses two patents in the U.S. and has a third patent pending. In addition, the Company has patents in Australia, Brazil, Canada, Japan, Korea and Russia, and through the European Patent Office, in Belgium, Switzerland, Germany, Denmark, Spain, France, Great Britain, Italy and the Netherlands.
Biomoda's business opportunities are in developing products for the early detection and targeted treatment of cancers. The initial products relate to lung cancer and are based on commercializing the Company's core patent protected technology. More information on the Company can be found at http://www.biomoda.com.
About Medical Acoustics
Medical Acoustics' mission is to design and develop devic
|SOURCE Biomoda, Inc.|
Copyright©2008 PR Newswire.
All rights reserved